Source Multiple Sclerosis News Today: 
Celgene released the results of two Phase 3 trials showing that patients with relapsing multiple sclerosis (MS) who were treated with ozanimod had lower relapse rates and fewer MRI brain lesions compared to those given a current first-line therapy, Avonex (interferon β-1a).
These results will be used to support a request for ozanimod’s approval as an MS therapy with the U.S. Food and Drug Administration (FDA), a filing known as a New Drug Application. Read on.